From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
Item
Status
ACTH
TCH
Deviation
Effect
Disease Free Survival/%
38%
46%
− 8
Death/%
2.6%
1.4%
1.2
QALY/Year
3.4
3.65
− 0.25
Intervention costsa($)
3112
1352
Health system costs($)
56,425
45,043
Cost($)
59,537
46,395
13,142
ICER
− 52,568